Akademik Veri Yönetim Sistemi
EXPERT OPINION ON PHARMACOTHERAPY, cilt.26, sa.14-15, ss.1589-1598, 2025 (SCI-Expanded, Scopus)
IntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD) has become a major public health concern. Recently, the development of liver-targeted pharmacologic therapies has gained momentum, culminating in the conditional approval of resmetirom which has generated renewed optimism for the management of MASLD. In addition, several other investigational agents have shown promising results in clinical trials.Areas coveredIn this review, we summarize the data on recent pharmacologic developments in the treatment of MASLD, with a particular focus on agents targeting the more progressive form - at-risk metabolic dysfunction-associated steatohepatitis (MASH). These therapies act through a variety of direct and indirect pathways within the liver.Expert opinionThe approval of liver-targeted therapies for MASH marks the beginning of a new era in disease management, offering promising outcomes even for advanced stages such as cirrhosis. The rising prevalence of obesity and T2DM suggests that new treatment options that can treat multiple comorbidities - including GLP1 receptor agonists, dual, and multi-agonists - are likely to play a significant role in the management of MASH. The availability of effective pharmacologic treatment options highlights the need for effective screening strategies in high-risk populations and call for the engagement of policymakers to develop coordinated plans at a global level.